onatasertib + ATG101

**Onatasertib + ATG101** is a combination therapy pairing **onatasertib (ATG-008)**, an oral small molecule dual inhibitor of mTORC1 and mTORC2, with **ATG-101**, a novel bispecific antibody targeting PD-L1 and conditionally activating 4-1BB to enhance anti-tumor immunity while minimizing systemic toxicity. Onatasertib disrupts the PI3K/AKT/mTOR signaling pathway critical for tumor cell proliferation and survival, synergizing with ATG-101's immune checkpoint blockade and costimulation to overcome resistance in solid tumors. Developed by **Antengene**, this pairing is preclinical, positioned as a next-generation immunotherapy combo potentially superior to onatasertib + PD-1 inhibitors, with ATG-101 in Phase 1 for advanced solid tumors and B-NHL.[7][12][15][16]